MCID: NSP002
MIFTS: 41

Nasopharyngitis

Categories: Oral diseases, Respiratory diseases

Aliases & Classifications for Nasopharyngitis

MalaCards integrated aliases for Nasopharyngitis:

Name: Nasopharyngitis 12 74 54 43 15 71
Chronic Nasopharyngitis 12 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:10460
ICD9CM 34 472.2
MeSH 43 D009304
NCIt 49 C34837
SNOMED-CT 67 47841006 51476001
ICD10 32 J00 J31.1
UMLS 71 C0027441 C0155826

Summaries for Nasopharyngitis

Disease Ontology : 12 A nasopharyngeal disease which involves inflammation of the nasal passages and upper part of the pharynx.

MalaCards based summary : Nasopharyngitis, also known as chronic nasopharyngitis, is related to pharyngitis and sleep apnea. An important gene associated with Nasopharyngitis is DPP4 (Dipeptidyl Peptidase 4), and among its related pathways/superpathways are Peptide hormone metabolism and Glucose / Energy Metabolism. The drugs Mirabegron and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, t cells and thyroid.

Wikipedia : 74 The common cold, also known simply as a cold, is a viral infectious disease of the upper respiratory... more...

Related Diseases for Nasopharyngitis

Diseases related to Nasopharyngitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1000)
# Related Disease Score Top Affiliating Genes
1 pharyngitis 33.5 TNFRSF1B GPT CRP
2 sleep apnea 31.1 INS GPT CRP
3 exanthem 30.9 TNFRSF1B GPT CYP3A4 CRP
4 pneumonia 30.8 TNFRSF1B IL17A GPT CRP
5 apnea, obstructive sleep 30.7 INS GCG CRP
6 aspiration pneumonia 30.4 INS IL17A GPT CRP
7 mycobacterium tuberculosis 1 30.4 TNFRSF1B PPIG IL17A CYP3A4 CRP
8 proteasome-associated autoinflammatory syndrome 1 30.3 TNFRSF1B INS IL17A CRP
9 syphilis 30.3 IL17A GPT CRP
10 bacterial pneumonia 30.3 IL17A GPT CRP
11 hepatitis a 30.2 INS GPT CYP3A4
12 endocarditis 30.1 TNFRSF1B IL17A CRP
13 malignant otitis externa 30.1 INS CRP
14 mucormycosis 30.1 PPIG INS CYP3A4
15 hypercholesterolemia, familial, 1 30.0 PCSK9 INS GPT CRP
16 peripheral nervous system disease 30.0 INS IL17A GPT GCG CRP
17 granulomatosis with polyangiitis 30.0 TNFRSF1B IL17A CRP
18 iridocyclitis 30.0 TNFRSF1B IL17A CRP
19 bilirubin metabolic disorder 29.9 GPT CYP3A4 CRP
20 autoimmune disease 29.9 TNFRSF1B INS IL17A DPP4 CRP
21 hyperthyroidism 29.9 INS GPT CRP
22 cholangitis 29.9 IL17A GPT CRP
23 conidiobolomycosis 29.8 PPIG CYP3A4
24 mediastinitis 29.7 INS CRP
25 hypoglycemia 29.7 INS GLP1R GCG DPP4
26 optic nerve disease 29.6 PDE5A IL17A CRP
27 pulmonary disease, chronic obstructive 29.2 PPIG PDE5A INS IL17A CRP
28 migraine with or without aura 1 29.1 PDE5A INS CYP3A4 CRP AMELX
29 hyperglycemia 28.9 SLC5A2 INS GLP1R GIP GCG DPP4
30 malaria 28.6 TNFRSF1B INS IL17A GPT CYP3A4 CRP
31 diabetes mellitus 28.0 SLC5A2 PDE5A INS IL17A GPT GLP1R
32 nasopharyngeal carcinoma 12.9
33 nasopharyngeal carcinoma 3 12.7
34 nasopharyngeal carcinoma 2 12.6
35 juvenile nasopharyngeal angiofibroma 12.6
36 nasopharyngeal disease 12.4
37 nasopharyngeal teratoma 12.3
38 dandy-walker malformation with nasopharyngeal teratoma and diaphragmatic hernia 12.2
39 lymphoepithelioma-like carcinoma 12.0
40 common cold 11.9
41 otosalpingitis 11.2
42 otitis media 10.8
43 haemophilus influenzae 10.8
44 diphtheria 10.8
45 mucositis 10.8
46 chronic rhinitis 10.8
47 myiasis 10.7
48 neutropenia 10.7
49 fibroma 10.6
50 teratoma 10.6

Graphical network of the top 20 diseases related to Nasopharyngitis:



Diseases related to Nasopharyngitis

Symptoms & Phenotypes for Nasopharyngitis

Drugs & Therapeutics for Nasopharyngitis

Drugs for Nasopharyngitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mirabegron Approved Phase 4 223673-61-8 9865528
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3 Neurotransmitter Agents Phase 4
4 Adrenergic Agonists Phase 4
5 Adrenergic beta-Agonists Phase 4
6 Muscarinic Antagonists Phase 4
7 Cholinergic Antagonists Phase 4
8 Adrenergic beta-3 Receptor Agonists Phase 4
9 Cholinergic Agents Phase 4
10 Solifenacin succinate Phase 4 242478-38-2
11 Adrenergic Agents Phase 4
12 Gastrointestinal Agents Phase 4
13 Proton Pump Inhibitors Phase 4
14 Anti-Ulcer Agents Phase 4
15 Antacids Phase 4
16
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
17 Siltuximab Approved, Investigational Phase 1, Phase 2 541502-14-1
18
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
19 Pharmaceutical Solutions Phase 2
20 Proteasome Inhibitors Phase 2
21 Antibodies, Monoclonal Phase 2
22 Interleukin-2 Phase 2
23 Immunologic Factors Phase 2
24 Antineoplastic Agents, Immunological Phase 2
25 Zanolimumab Phase 2
26 Analgesics, Non-Narcotic Phase 2
27 Anti-Infective Agents Phase 2
28 Anti-Retroviral Agents Phase 2
29 Antiviral Agents Phase 2
30 Anti-HIV Agents Phase 2
31 Analgesics Phase 2
32 Immunoglobulins Phase 2
33 Antibodies Phase 2
34
4-Aminopyridine Approved 504-24-5 1727
35
Atorvastatin Approved 134523-00-5 60823
36 Anti-Bacterial Agents
37 Antibiotics, Antitubercular
38 Hypolipidemic Agents
39 Anticholesteremic Agents
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors
41 Lipid Regulating Agents
42 Antimetabolites
43 Acidophilus

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
2 Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study Recruiting NCT04028466 Phase 4 Vonoprazan;Omeprazole
3 Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study) Completed NCT01873157 Phase 2 Bortezomib;Placebo
4 A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2 Siltuximab;normal saline
5 Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer Terminated NCT01160445 Phase 2 Zanolimumab;Aldesleukin
6 An Open-Label Trial of Tocilizumab in Schizophrenia Completed NCT01696929 Phase 1 Tocilizumab
7 A Randomized Controlled Trial of Adjunctive Tocilizumab in Schizophrenia Recruiting NCT02874573 Phase 1 Tocilizumab;Normal saline
8 A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy Unknown status NCT03379610
9 Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Pilot Study) Completed NCT01454960
10 Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study) Completed NCT01454947
11 Observational Study for Assessment of the Effect of Fampyra on the Manual Function of Persons With Multiple Sclerosis Completed NCT01547234
12 Post-market Study of AMAP Receptor Antagonists for Epilepsy Patients in Hong Kong Recruiting NCT03457961 Perampanel
13 The Effect of Seven-Day Atorvastatin Administration on Emotional Processing, Reward Processing, and Inflammation in Healthy Volunteers Recruiting NCT03966859 Atorvastatin 20mg
14 Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation Terminated NCT01315418

Search NIH Clinical Center for Nasopharyngitis

Cochrane evidence based reviews: nasopharyngitis

Genetic Tests for Nasopharyngitis

Anatomical Context for Nasopharyngitis

MalaCards organs/tissues related to Nasopharyngitis:

40
Pituitary, T Cells, Thyroid, Kidney, Lung, Bone, B Cells

Publications for Nasopharyngitis

Articles related to Nasopharyngitis:

(show top 50) (show all 944)
# Title Authors PMID Year
1
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. 54 61
17622601 2007
2
Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study. 61
31837113 2020
3
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. 61
31404668 2020
4
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. 61
31820485 2020
5
A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine. 61
32037549 2020
6
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. 61
31374300 2020
7
Interventions for chronic palmoplantar pustulosis. 61
31958161 2020
8
Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Topical Corticosteroids: Results from Two Randomised Monotherapy Phase 3 Trials. 61
31995838 2020
9
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. 61
31595499 2020
10
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. 61
31449914 2020
11
Interventions for chronic pruritus of unknown origin. 61
31981369 2020
12
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. 61
31813637 2020
13
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis. 61
31984480 2020
14
Adverse Events of Injectable Deoxycholic Acid. 61
31977503 2020
15
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. 61
31964419 2020
16
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. 61
31593702 2020
17
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study. 61
31883082 2020
18
Breastfeeding initiation or duration and longitudinal patterns of infections up to 2 years and skin rash and respiratory symptoms up to 8 years in the EDEN mother-child cohort. 61
31970921 2020
19
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study. 61
31758520 2020
20
Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies. 61
31954998 2020
21
Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. 61
31812127 2020
22
Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. 61
31912493 2020
23
Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. 61
31494097 2019
24
Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. 61
31755090 2019
25
Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. 61
31891449 2019
26
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer. 61
31446511 2019
27
Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. 61
31926465 2019
28
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. 61
31697801 2019
29
Rhinorrhea as a Result of Alzheimer's Disease Treatment: A Case Report. 61
31818352 2019
30
Dupilumab for atopic dermatitis: evidence to date. 61
31210470 2019
31
Tiotropium in children and adolescents with asthma. 61
31805357 2019
32
A Phase 2a Study of DP2 antagonist GB001 for Asthma. 61
31778823 2019
33
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. 61
31543428 2019
34
Correlation between IL-17A expression in nasopharyngeal carcinoma tissues and cells and pathogenesis of NPC in endemic areas. 61
31456038 2019
35
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study. 61
32038757 2019
36
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. 61
31714986 2019
37
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. 61
31612482 2019
38
Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial. 61
31748467 2019
39
Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. 61
31691827 2019
40
Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. 61
31722446 2019
41
Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. 61
31721310 2019
42
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. 61
30367462 2019
43
Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials. 61
31810577 2019
44
Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. 61
31721327 2019
45
Treatments for seizures in catamenial (menstrual-related) epilepsy. 61
31608992 2019
46
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. 61
31578954 2019
47
Burden of Asthma and Role of 2.5 µg Tiotropium Respimat® as an Add-On Therapy: A Systematic Review of Phase 2/3 Trials. 61
31435830 2019
48
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. 61
31671432 2019
49
Short-term and long-term effects of PM2.5 on acute nasopharyngitis in 10 communities of Guangdong, China. 61
31229811 2019
50
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. 61
31345778 2019

Variations for Nasopharyngitis

Expression for Nasopharyngitis

Search GEO for disease gene expression data for Nasopharyngitis.

Pathways for Nasopharyngitis

GO Terms for Nasopharyngitis

Cellular components related to Nasopharyngitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNFRSF1B PCSK9 INS IL17A GIP GCG
2 endoplasmic reticulum lumen GO:0005788 9.02 PCSK9 INS GIP GCG AMELX

Biological processes related to Nasopharyngitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of blood vessel diameter GO:0097756 8.96 CRP INS
2 regulation of insulin secretion GO:0050796 8.92 DPP4 GCG GIP GLP1R

Molecular functions related to Nasopharyngitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 SEPTIN3 INS GCG DPP9 DPP4 CRP
2 low-density lipoprotein particle binding GO:0030169 9.32 PCSK9 CRP
3 dipeptidyl-peptidase activity GO:0008239 9.26 DPP8 DPP4
4 glucose:sodium symporter activity GO:0005412 8.96 SLC5A4 SLC5A2
5 serine-type peptidase activity GO:0008236 8.92 PCSK9 DPP9 DPP8 DPP4

Sources for Nasopharyngitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....